INVICTUS: A phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as ≥ 4th-line therapy in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies (NCT03353753) Meeting Abstract
| Authors: | von Mehren, M.; Serrano, C.; Bauer, S.; Gelderblom, H.; George, S.; Heinrich, M.; Schöffski, P.; Zalcberg, J.; Chi, P.; Jones, R. L.; Reichardt, P.; Attia, S.; D'Amato, G.; Meade, J.; Shi, K.; Ruiz-Soto, R.; Blay, J. Y. |
| Abstract Title: | INVICTUS: A phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as ≥ 4th-line therapy in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies (NCT03353753) |
| Meeting Title: | 44th ESMO Congress (ESMO 2019) |
| Journal Title: | Annals of Oncology |
| Volume: | 30 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2019 Sep 27-Oct 1 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2019-10-01 |
| Start Page: | mdz394.087 |
| Language: | English |
| ACCESSION: | WOS:000491295500211 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdz394.087 |
| Notes: | Meeting Abstract: LBA87 -- Appears on pages v925-v926 of the abstract book -- Source: Wos |
